Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.

摘要: BACKGROUND: The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity. AIM: To assess EIM in patients with inflammatory bowel disease (IBD) large real-life experience cohort. METHODS: Between June and December 2014, 173 Crohn's 121 ulcerative colitis were treated vedolizumab. Patients followed until week 54. activity was assessed at weeks 0, 6, 14, 22, 30 54 by using 3-step scale: complete remission, partial response no response. RESULTS: At baseline, 49 (16.7%) had EIMs which 47 arthralgia/arthritis, four cutaneous lesions two both rheumatologic skin EIM. At 54, 21 (44.7%) remission arthralgia/arthritis three (75%) In multivariate analysis, associated clinical IBD (OR = 1.89, IC95% [1.05-3.41], P .03) recent onset 1.99, [1.12-3.52], .02). During the follow-up period, 34 (13.8%) without any developed incident cases consisting mostly peripheral arthralgia evidence arthritis 14 (4.8%) paradoxical manifestation. CONCLUSION: Vedolizumab therapy commonly improvement This quiescent However, manifestation may occur upon therapy. © 2017 John Wiley & Sons Ltd.